![]() ![]() The other drug Silverback has abandoned, SBT6290, uses the same linker payload conjugated to a Nectin4 antibody. The TLR8 agonist is designed to target those cells, theoretically activating human myeloid cells expressing HER2 and triggering the innate immune system to drive anti-tumor responses. TLR8 is expressed in myeloid cells, which are present in tumors. SBT6050 comprises a small molecule toll-like receptor 8 (TLR8) agonist conjugated to a HER2-directed monoclonal antibody. However, the company this week said that while some patients had a dose-related response in that study, it decided to stop further development "based on limited monotherapy anti-tumor activity and cytokine-related adverse events" that would limit the acceptable dose of SBT6050 that patients could receive in combination with Merck's checkpoint inhibitor Keytruda (pembrolizumab). At the time, Silverback said that SBT6050 was generally well-tolerated with a "manageable" adverse event profile. In September 2021, Silverback reported results from a Phase I/Ib study of SBT6050 in HER2-expressing solid tumors. In reporting its 2021 financial results on Thursday, the Seattle-based company said it would discontinue developing two antibody-drug conjugates, SBT6050 and SBT6290, in biomarker-informed cancer indications. NEW YORK – Silverback Therapeutics is shutting down its targeted oncology programs and cutting its workforce by 27 percent as it refocuses resources on developing chronic hepatitis B drugs and its ImmunoTAC drug discovery platform. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |